Flexible dosing of Tincture of Opium in the management of opioid withdrawal: Pharmacokinetics and pharmacodynamics

British Journal of Clinical Pharmacology

Volumn 66, Issue 5, 2008, Pages 640-647

  Somogyi, Andrew A ^a   Larsen, Mie ^b   Abadi, Reza M ^b   Jittiwutikarn, Jaroon ^c   Ali, Robert ^a   White, Jason M ^a,d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Northern Drug Dependence Centre   (Thailand)

^d Drug & Alcohol Services South Australia   (Australia)

Author keywords

Opioid dependence; Pharmacodynamics; Pharmacokinetics; Thailand; Tincture of opium

Indexed keywords

MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; OPIATE;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BREATHING DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOTENSION; MALE; MASS SPECTROMETRY; OPIATE ADDICTION; PHARMACODYNAMICS; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; TINCTURE; WITHDRAWAL SYNDROME;

EID: 55149105691     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03277.x     Document Type: Article

References (24)

1. Holmstrand J, Anggård E, Gunne LM. Methadone maintenance: plasma levels and therapeutic outcome. Clin Pharmacol Ther 1978 23 : 175 80.
2. Schall U, Pries E, Katta T, Kloppel A, Gastpar M. Pharmacokinetic and pharmacodynamic interactions in an outpatient maintenance therapy of intravenous heroin users with levomethadone. Addict Biol 1996 1 : 105 13.
3. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet 1999 353 : 221 6.
4. Bell J, Mattick R, Hay A, Chan J, Hall W. Methadone maintenance and drug-related crime. J Subst Abuse 1997 9 : 15 25.
5. Grøndbladh L, Ohlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand 1990 82 : 223 7.
6. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann NY Acad Sci 2000 909 : 186 216.
7. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behaviour and criminality: a meta-analysis. Addiction 1998 93 : 515 32.
8. Metzger DS, Woody GE, McLellan AT, O'Brien CP, Druley P, Navaline H, DePhilippis D, Stolley P, Abrutyn E. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18 month prospective follow-up. J Acquir Immune Defic Syndr 1993 6 : 1049 56.
9. Jittiwutikarn J, Ali R, White J, Bochner F, Somogyi AA, Foster DJ. Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. Br J Clin Pharmacol 2004 58 : 536 41.
10. WHO/UNODC/UNAIDS. Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention: position paper. 2004. Available at http://www.who.int/substance_abuse/publications/en/PositionPaper_English.pdf (last accessed 27 March 2008).
11. Auriacombe M, Grabot D, Daulouede J-P, Vergnolle J-P, O'Brien C, Tignol JA. Naturalistic follow-up study of French-speaking opiate-maintained heroin-addicted patients: effect of biopsychosocial status. J Subst Abuse Treat 1994 11 : 565 8.
12. Sarka S, Donn SM. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J. Perinatol 2006 26 : 15 7.
13. Coyle MG, Ferguson A, Lagasse L, Oh W, Lester B. Diluted tincture of opium (DTO) and phenobarbitol versus DTO alone for neonatal opiate withdrawal in term infants. J Pediatr 2002 140 : 561 4.
14. Langenfield S, Birkenfeld L, Herkenrath P, Muller C, Hellmich M, Theisohn M. Therapy of neonatal abstinence syndrome with tincture of opium or morphine drops. Drug Alcohol Depend 2005 77 : 31 6.
15. Antonilli L, Semeraro F, Suriano C, Signore L, Nencini P. High levels of morphine-6-glucuronide in street heroin addicts. Psychopharmacology 2003 170 : 200 4.
16. Dyer KR, Foster DJ, White JM, Somogyi AA, Menelaou A, Bochner F. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther 1999 65 : 685 94.
17. Doverty M, Somogyi AA, White JM, Bochner F, Beare CH, Menelaou A, Ling W. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain 2001 93 : 155 63.
18. Milne RW, Nation RL, Reynolds GD, Somogyi AA, van Crugten JT. High performance liquid chromatographic determination of morphine and its 3- and 6-glucuronide metabolites: improvements to the method and application to stability studies. J Chromatogr Biomed Appl 1991 565 : 457 64.
19. Säwe J, Svensson JO, Rane A. Morphine metabolism in cancer patients on increasing oral doses - no evidence for autoinduction or dose dependence. Br J Clin Pharmacol 1983 16 : 85 93.
20. Nemann PB, Henriksen H, Grosman N, Broen Christensen C. Plasma morphine concentrations during chronic oral administration in patients with cancer pain. Pain 1982 13 : 247 52.
21. Ashby M, Fleming B, Wood M, Somogyi A. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. J Pain Symptom Manage 1997 14 : 157 67.
22. Somogyi AA, Nation RL, Olweny C, Tsirgiotis P, van Crugten J, Milne RW, Cleary JF, Danz C, Bochner F. Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine. Clin Pharmacokinet 1993 24 : 413 20.
23. Wolff T, Samuelsonn H, Hedner T. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration. Pain 1995 62 : 147 54.
24. Westerling D, Personn C, Höglund P. Plasma concentration of morphine, morphine-3-glucuronide, and morphine-6-glucuronide after intravenous and oral administration to healthy volunteers: relationship to nonanalgesic actions. Ther Drug Monit 1995 17 : 287 301.